Unicorn Bio

Unicorn Biotechnologies (Unicorn Bio) develops automated cell culture systems — machines, consumables and services — intended to standardize and industrialize mammalian cell culture workflows, with particular focus on induced pluripotent stem cells (iPSCs). Its stated aim is to remove manual liquid-handling and flask-transfer work from laboratory workflows so that scientists can concentrate on experimental design and analysis, and to provide processes that transfer to linearly scalable systems from bench through pilot and commercial manufacturing [0][1][6].

The company's first product is Emmet, described as an intelligent benchtop instrument that automates tissue-culture flask workflows through a unified hardware and software stack and applies machine learning in the tissue culture lab [2]. Published application notes report automated expansion of hiPSCs from a T25 to a T225 flask in a closed, automated benchtop system, and automated hiPSC differentiation into cardiomyocytes at greater than 96% purity [0][5]. Third-party profiles describe a pipeline that also includes GMP-ready and early-discovery systems, along with contract R&D services such as cell line engineering, bioassays and LNP delivery [6].

Secondary sources characterize the addressable applications as drug discovery, regenerative medicine, cell and gene therapy, and cultivated meat [6][7]. Note that reported firmographics differ across sources: Startup Intros lists founding in 2020 and an HQ in Cambridge, UK with an employee range of 1001-5000, while Caplight lists founding in 2020, an HQ in Sheffield and roughly 15 employees; the company's own materials place its laboratory operations in Sheffield [0][5][6][7].

Founding story

Startup Intros reports the company was co-founded by Adam Glen and Jack Reid, with Glen described as holding a PhD in cancer research and prior experience in academia, GE Healthcare and biotech startups, specializing in stem cell biology, tissue engineering and hardware for life sciences. The stated origin was frustration with manual cell culture methods described as largely unchanged since the 1950s, and the view that these methods constrain both scientific progress and the scalability of cell-based therapies [6]. The company's own mission page frames the goal as creating tools to standardize and industrialize cell biology [4].

Business model

B2B supplier of laboratory hardware to life-science organizations, characterized by Caplight as combining hardware sales, services and consulting, and hardware plus subscription [7]. Startup Intros describes a "picks and shovels" positioning supplying tools to other biology organizations rather than developing therapeutics itself [6].

Reported revenue streams include sales of instruments and consumables, contract R&D and cellular/molecular biology services, near-term licensing of engineered cell lines, and a "Cell-manufacturing-as-a-Service" offering aimed at cell and gene therapy, pharma and cultivated meat customers [6][7].

Traction

Publicly verifiable traction is limited. The company has published two Emmet application notes (January and July 2025) demonstrating automated hiPSC expansion and cardiomyocyte differentiation [5], relocated its scientists and engineers into a refurbished Sheffield city-centre laboratory in September 2024 [0][5], and lists a team of roughly nine named staff on its site [3]. Caplight records a single market signal of monthly website visitors reaching about 4,000, up 85% month over month [7]. Customer testimonials on the website are attributed to individuals at MedTech Solutions, BioGenix Labs and PharmaVentures Inc., but no independent confirmation of these relationships appears in the sources [0].

Latest developments

Most recent dated company output is a July 2025 application note reporting that Emmet automates hiPSC differentiation into cardiomyocytes at greater than 96% purity, following a January 2025 note on automated hiPSC expansion from T25 to T225 in a closed benchtop system [0][5]. Caplight records a market signal dated June 2026 noting monthly website visitors up 85% month over month to about 4,000, and lists the April 2022 seed as the most recent funding round [7].